top of page

About Us

Scilentia's Global Partners have more than 50 years of combined global biopharma experience, earned in the top executive ranks of

Fortune 10 pharmas and world-class biotechs.

In total, our team has personally launched products that have delivered over 

$50 billion in actual or projected peak revenue.

They have founded and advised >50 biotech start-ups

that have successfully raised more than $400 million in combined funding. 

Scilentia's expert guidance is not theoretical --

it's anchored in the battle-hardened realities of

leading therapeutic development and commercialization

Meet two of our Global Partners 
Untitled image.jpg

Michael Williams

  • LinkedIn

Global Partner

Michael has extensive experience from his work at major pharmaceutical companies and emerging startups. He's served as a CEO, CCO, Head of Global Marketing and Board member. His experience and expertise enables him to provide Scilentia clients with a broad view of differing market dynamics and business strategies, that is invaluable for startups navigating the complex landscape of drug development and commercialization.

In particular, Michael is able to coach clients on how to innovate  and operate efficiently in a range of competitive settings. He has personally experienced the challenges of translating scientific breakthroughs into viable business models, and successfully led his teams through this process.

Michael is also a venture investor and advisor.  This experience enables him to bring astute business development and investment advice to his biotech clients. His history of evaluating and investing in promising ventures adds an invaluable aspect to his advisory role at Scilentia.

KDetrick Head shot (1)_edited.jpg

Kirsten Detrick

  • LinkedIn

Global Partner

Kirsten has launched multiple products across a variety of therapeutic areas, at several multi-national drug companies and start-ups. Her pivotal experiences as CEO, CCO, Portfolio Leader and Adjunct Professor of Business enable her to guide teams toward strategically and tactically anchored launch frameworks that deliver value based on true differentiation - critical for startups operating in hyper-competitive environments, under intense resource constraints.

Kirsten's proven ability to anchor product success in scientific differentiation, commercialization strategy, and access/ reimbursement environments helps her guide startups through Scilentia's programs to ensure that products are positioned competitively to optimize both patient and financial value. 

Kirsten has built a particular capability in navigating collaborations and partnerships. She has originated these tricky relationships and also repaired them for a range of exciting life-sciences organizations.

bottom of page